We are live on ! Find out more
NXTM

NxStage Medical Inc.
NXTM

Delisted

NXTM was delisted on the 21st of February, 2019.

171 hedge funds and large institutions have $1.59B invested in NxStage Medical Inc. in 2018 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 48 increasing their positions, 59 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 24

12% more capital invested

Capital invested by funds: $1.42B → $1.59B (+$168M)

2% more funds holding

Funds holding: 168171 (+3)

4% less call options, than puts

Call options by funds: $1.92M | Put options by funds: $1.99M

13% less funds holding in top 10

Funds holding in top 10: 87 (-1)

19% less repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 59

Holders
171
Holders Change
+3
Holders Change %
+1.79%
% of All Funds
3.91%
Holding in Top 10
7
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-12.5%
% of All Funds
0.16%
New
28
Increased
48
Reduced
59
Closed
24
Calls
$1.92M
Puts
$1.99M
Net Calls
-$70K
Net Calls Change
-$404K
Name Holding Trade Value Shares
Change
Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$164M +$4.75M +177,153 +3%
BlackRock
2
BlackRock
New York
$148M +$13.5M +501,922 +10%
TAL
3
TIG Advisors LLC
New York
$97.3M +$47.9M +1,787,017 +105%
AAM
4
Alpine Associates Management
Florida
$93.1M +$812K +30,300 +0.9%
MF
5
Magnetar Financial
Illinois
$85.6M +$348K +12,969 +0.4%
AA
6
AQR Arbitrage
Connecticut
$80.5M -$3.35M -124,862 -4%
Flossbach Von Storch
7
Flossbach Von Storch
Germany
$76.2M -$6.99M -260,786 -9%
State Street
8
State Street
Massachusetts
$42.7M +$2.68M +99,885 +7%
WIC
9
Water Island Capital
New York
$37.2M +$4.01M +149,713 +13%
Grantham, Mayo, Van Otterloo & Co (GMO)
10
Grantham, Mayo, Van Otterloo & Co (GMO)
Massachusetts
$28.4M -$10.9M -406,365 -29%
Citigroup
11
Citigroup
New York
$28.1M +$744K +27,730 +3%
UBS Group
12
UBS Group
Switzerland
$27.4M +$13M +483,274 +97%
UOC
13
UBS O'Connor
Illinois
$26.2M +$8.15M +304,033 +48%
State of Wisconsin Investment Board
14
State of Wisconsin Investment Board
Wisconsin
$25.8M -$4.85M -180,973 -16%
Northern Trust
15
Northern Trust
Illinois
$24.7M +$687K +25,633 +3%
Marshall Wace
16
Marshall Wace
United Kingdom
$24.4M -$3.78M -141,097 -14%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$22.3M +$783K +29,207 +4%
Norges Bank
18
Norges Bank
Norway
$22.3M -$1.16M -43,204 -5%
OAM
19
Oxford Asset Management
United Kingdom
$22.2M
AWG
20
Alpha Wave Global
New York
$22.1M
JP Morgan Chase
21
JP Morgan Chase
New York
$21.2M -$18.3M -684,166 -47%
Goldman Sachs
22
Goldman Sachs
New York
$21M -$8.57M -319,563 -30%
Bank of New York Mellon
23
Bank of New York Mellon
New York
$16.9M +$803K +29,934 +5%
Wells Fargo
24
Wells Fargo
California
$15.7M +$3.38M +126,071 +29%
WCMNY
25
Westchester Capital Management (New York)
New York
$14.7M +$14.1M +527,494 New

NXTM Hedge Fund Activity: Q2 2018 in Review

171 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in NxStage Medical Inc. (NXTM) for Q2 2018, worth a combined $1.59B — up 12% from $1.42B a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new NXTM positions and 24 closed out — a net gain of 4 holders — while 48 added to existing stakes and 59 trimmed.

The largest buyer was TIG Advisors LLC, adding an estimated $47.9M. The largest seller was Pennant Capital Management, cutting an estimated $37.4M.

  • 171 institutional investors held NxStage Medical Inc. (NXTM) as of Q2 2018, up from 168 in Q1 2018.
  • Funds reported $1.59B of NxStage Medical Inc. stock for Q2 2018, up 12% quarter-over-quarter.
  • 28 funds opened new NxStage Medical Inc. positions in Q2 2018 and 24 closed out, a net change of +4 holders.
  • The largest NxStage Medical Inc. buyer in Q2 2018 was TIG Advisors LLC, an estimated $47.9M added.
  • The largest NxStage Medical Inc. seller in Q2 2018 was Pennant Capital Management, an estimated $37.4M sold.

Based on aggregated 13F filings for Q2 2018.